EKR Therapeutics Appoints John Bailye as Interim President & Chief Executive Officer

EKR Therapeutics Appoints John Bailye as Interim President & Chief Executive Officer
Bedminster, N.J., March 3, 2010 - EKR Therapeutics, Inc., a specialty pharmaceutical company focused on commercializing acute-care hospital products, today announced that its Executive Chairman John Bailye has been appointed Interim President and Chief Executive Officer replacing Howard Weisman who is no longer with the Company. Mr. Weisman will also no longer serve on EKR's Board of Directors.

About EKR Therapeutics
EKR Therapeutics is a specialty pharmaceutical company focused on acquiring, developing and maximizing the potential utility of critical-care hospital products offering broader therapeutic options and greater control to improve in-patient care, speed recovery, and achieve optimal outcomes.  Backed by the strength of its award winning management team, the dedication of its field force of product specialists and its commitment to excellence in customer service and medical education, EKR has been organized to be a class leader in commercializing products to address unmet and under-satisfied medical needs or to otherwise enhance the therapeutic value of acute-care products. For additional information about EKR visit the Company's website at www.ekrtx.com.


Contact for EKR Therapeutics
Stuart Z. Levine, Ph.D.
Director, Strategic Communications
[email protected]

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.